Medical Devices

Paragonix Technologies Announces Nationwide Commercial Availability of FDA-Cleared BAROguard™ Donor Lung Preservation System

Retrieved on: 
Thursday, April 4, 2024
FDA, Health Technology, Health, Medical Devices, Lung, Massachusetts General Hospital, International Society, Transplant, Patient, Duke University Hospital, Research, Standard of care, Lung transplantation, MD, Surgeon, MSC, UCSF Medical Center, Atmosphere, Hospital, UCLA, Heart, UCLA Health, Medical device

Paragonix Technologies, Inc. , a pioneer in organ transplant technologies and procurement services, announces the full commercial launch of its next-generation transport device, the BAROguard™ Donor Lung Preservation System .

Key Points: 
  • Paragonix Technologies, Inc. , a pioneer in organ transplant technologies and procurement services, announces the full commercial launch of its next-generation transport device, the BAROguard™ Donor Lung Preservation System .
  • First-of-its-kind, the novel BAROguard system combines clinically proven hypothermic preservation techniques alongside active airway management control to ensure that donor lungs maintain optimal conditions during transport for maximum protection.
  • Paragonix Technologies received FDA 510(k) clearance for the device in August 2023, and conducted its first-in-human case at Duke University Medical Center in November 2023.
  • “The commercial launch of BAROguard represents a significant breakthrough for the organ transplantation industry,” said Dr. Lisa Anderson, CEO and President of Paragonix Technologies.

Heart Rhythm Clinical and Research Solutions and the Real World Evidence Consortium Launch EVERCOOL AF Study on Attune Medical’s ensoETM®

Retrieved on: 
Thursday, April 4, 2024
Research, Medical Devices, Surgery, Medical Supplies, Hospitals, Cardiology, Other Health, Pharmaceutical, Health, Science, Real, RWE, Atrial fibrillation, Procedural, Multimedia

Heart Rhythm Clinical and Research Solutions (HRCRS) and the Real World Evidence (RWE) Consortium have enrolled the first patient in the REView of ProcEdural FactoRs and Outcomes after Atrial Fibrillation Ablation with Active Esophageal COOLing (EVERCOOL AF) study.

Key Points: 
  • Heart Rhythm Clinical and Research Solutions (HRCRS) and the Real World Evidence (RWE) Consortium have enrolled the first patient in the REView of ProcEdural FactoRs and Outcomes after Atrial Fibrillation Ablation with Active Esophageal COOLing (EVERCOOL AF) study.
  • The study is part of a multi-center observational study evaluating the impact of proactive esophageal cooling on patient outcome, throughput, and experience in high volume centers.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240404481691/en/

Revvity To Hold Earnings Call on Monday, April 29, 2024

Retrieved on: 
Thursday, April 4, 2024
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical

Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2024 financial results prior to market open on Monday, April 29, 2024.

Key Points: 
  • Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2024 financial results prior to market open on Monday, April 29, 2024.
  • The Company will host a conference call the same day at 8:00 a.m.
  • Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.
  • To access the call, a live audio webcast will be available via this registration form or on the Investors section of the Company's website.

MMS Hires Pharmaceutical Industry Veteran James Zee for Global Biometrics Leadership in Europe Amid Strong Regional Growth

Retrieved on: 
Thursday, April 4, 2024
Data Management, Technology, Pharmaceutical, Professional Services, Biometrics, Medical Devices, Genetics, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Data Analytics, Health, Research, MSD, American City Business Journals, Growth, AstraZeneca, Data science, Novartis, Patient, Roche, MMS, RWD, AI, Statistics, Data management, Drug development, NCE, FSP, Zee, Fine chemical

MMS, a leading, data-focused clinical research organization (CRO), announced today that the company has expanded its biometrics leadership within European operations by hiring James Zee as Director of Global Statistical Programming.

Key Points: 
  • MMS, a leading, data-focused clinical research organization (CRO), announced today that the company has expanded its biometrics leadership within European operations by hiring James Zee as Director of Global Statistical Programming.
  • Based in the United Kingdom (UK), Zee brings 25 years of experience across several leading pharmaceutical companies, including AstraZeneca, MSD, Novartis, Roche, and others.
  • With extended drug development experience, Zee helps to guide the statistical programming team at MMS to support some of the timely execution and evolving regulations for the development of NCEs.
  • Since 2020, the global biometrics CRO has experienced 133 percent growth in Europe.

Velsera and Flywheel Team up to Support Multimodal Imaging Genomics Research

Retrieved on: 
Thursday, April 4, 2024
Other Health, General Health, Radiology, Pharmaceutical, Medical Devices, Technology, Hospitals, Artificial Intelligence, Genetics, Health Technology, Biotechnology, Health, Genomics, Algorithm, MRI, FHIR, Down syndrome, Environment, Investigation, Disease, Patient, Artificial intelligence, AI, PB, NIH, Ecosystem, Privacy, Government, Syndrome, Metadata, Medical imaging

Combining their capabilities, Velsera, Flywheel, and D3b were able to manage, harmonize, and analyze large datasets in a cloud-based platform.

Key Points: 
  • Combining their capabilities, Velsera, Flywheel, and D3b were able to manage, harmonize, and analyze large datasets in a cloud-based platform.
  • The Velsera team created interoperability standards that allow platforms to communicate with each other and make large-scale data access transparent to the user.
  • “Linking our Flywheel Core Platform with Velsera’s CAVATICA platform facilitates an unparalleled ability to perform advanced, multimodal data analysis in a cloud environment,” said Travis Richardson, Chief Strategist at Flywheel.
  • Using data from D3b, teams were able to analyze the combination of extracted imaging features on the Flywheel Core Platform.

Biolinq Raises $58 Million to Advance Wearable Biosensors Through Pivotal Trial for Metabolic Health Using Precision Microsensor Technology

Retrieved on: 
Thursday, April 4, 2024
Research, Other Health, Pharmaceutical, Technology, Medical Devices, Clinical Trials, Science, Nanotechnology, Biotechnology, Wearables, Mobile Technology, Health, Diabetes, Other Science, Aphelion, AXA, Taisho Pharmaceutical, Skin, Bleeding, Needle, Multimedia, FDA, Incorporated, Silicon

J.P. Morgan served as placement agent to Biolinq in connection with the financing.

Key Points: 
  • J.P. Morgan served as placement agent to Biolinq in connection with the financing.
  • “Our technology approach enables access to a coveted, metabolically active compartment of the skin for biosensing without the use of introducer needles or bleeding,” said Rich Yang, CEO, Biolinq.
  • “Companies that disrupt entire industries often don’t originate from a single discipline,” said Rick Gerson, Chairman of Alpha Wave Global.
  • “Biolinq has attracted leading experts in biosensor development, consumer electronics design, proprietary materials science, software engineering and semiconductor manufacturing to build a new category of biowearables.

Fortune Media and Great Place To Work Name Vizient to ‘100 Best Companies to Work For’ in 2024

Retrieved on: 
Thursday, April 4, 2024
Professional Services, Pharmaceutical, Business, Medical Devices, Hospitals, Publishing, Data Analytics, Communications, Medical Supplies, Human Resources, Practice Management, Health, Consulting, HR, Culture, Organization, Growth, Face, Consultant, PEOPLE, Trust, Workplace

Great Place To Work® and Fortune magazine have recognized Vizient as one of the Fortune 100 Best Companies to Work For® in 2024.

Key Points: 
  • Great Place To Work® and Fortune magazine have recognized Vizient as one of the Fortune 100 Best Companies to Work For® in 2024.
  • Earning a spot means that Vizient is one of the best companies to work for in the country.
  • The 100 Best Companies to Work For list is the only recognition that focuses on how employees feel about their workplace.
  • Great Place To Work evaluates confidential feedback from employees, matching against HR data from participating companies.

Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment

Retrieved on: 
Thursday, April 4, 2024
Research, Professional Services, Data Management, Oncology, Technology, Medical Devices, Genetics, Artificial Intelligence, Health Technology, Data Analytics, Science, Biotechnology, Health, Cloud, Algorithm, Individualized medicine, Exact sciences, Disease, Physician, Risk, Patient, Mayo Clinic, DNA, Cancer, Multimedia, Collection, Medical imaging

Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of an initiative with Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients.

Key Points: 
  • Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of an initiative with Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients.
  • View the full release here: https://www.businesswire.com/news/home/20240404198461/en/
    Initiative advances precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients at the Mayo Clinic Comprehensive Cancer Center (Graphic: Business Wire)
    “This collaboration supports our mission to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment,” said Kevin Conroy , chairman and chief executive officer, Exact Sciences.
  • The Riskguard hereditary cancer test helps patients and their physicians understand the patients' hereditary risk of cancer.
  • “It will also lead to new scientific and clinical discoveries by Mayo Clinic Comprehensive Cancer Center and Mayo Clinic's Center for Individualized Medicine .”
    Patients will consent to have the tests performed and to have the data shared with Mayo Clinic.

XCath CEO Eduardo Fonseca Spotlights AI in Endovascular Robotics at SLICE Next Frontiers Conference

Retrieved on: 
Thursday, April 4, 2024
Neurology, General Health, Health, Artificial Intelligence, Medical Devices, Robotics, Health Technology, Technology, AI, Conference, Exhibition, DRS

XCath , an early-stage medical device company dedicated to expanding endovascular treatment modalities through its robotic systems and steerable guidewires, presented at the annual SLICE Next Frontiers Conference hosted by Dr. Vincent Costalat and Master and Fellow .

Key Points: 
  • XCath , an early-stage medical device company dedicated to expanding endovascular treatment modalities through its robotic systems and steerable guidewires, presented at the annual SLICE Next Frontiers Conference hosted by Dr. Vincent Costalat and Master and Fellow .
  • “The SLICE Next Frontiers conference convenes thought leaders from across the neuro space and is a key opportunity to learn about current innovations and where we’re going next,” said Fonseca.
  • “In conversations that took place at the event about robotics, AI and telerobotics there was a lot of enthusiasm about how these technologies can enhance patient care.
  • These objectives are all top of mind at XCath, and we look forward to being part of the future of neurovascular interventions.”
    For more information about the SLICE Next Frontiers Conference, visit https://masterandfellow.com/slice/nf .

Global Mobile Medical Imaging Market Trends and Growth Analysis Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 4, 2024
Radiology, Health, Medical Devices, Row, COVID-19, Privacy, Computer security, Telehealth, POC, Medical device

The "Global Mobile Medical Imaging Market Trends and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Mobile Medical Imaging Market Trends and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • The report focuses on mobile imaging equipment for POC settings, enabling bedside imaging and remote diagnosis (excluding conventional, trailer-mounted mobile imaging equipment that users must transport to different locations).
  • There is a growing demand for mobile imaging equipment in low and middle-income countries due to the limited financial resources to procure, operate, and maintain expensive medical imaging equipment.
  • This study will provide the trends, challenges, drivers, restraints, competitive landscape, and growth opportunities for mobile medical imaging systems in different clinical settings, including at-home medical imaging and remote diagnosis.